Dublin, Sept. 27, 2018 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" report has been added to ResearchAndMarkets.com's offering.
The study scope includes clinical therapies using gene editing, gene therapy, genetically modified cell therapy (chimeric antigen receptor T-cells, or CAR T-cells) or RNA therapy platforms. Delivery technologies covered include AAV, adenovirus, lentivirus, retrovirus, other viral and nonviral. Disease areas covered include cardiology, oncology, ophthalmology, hematology, musculoskeletal, neurology, rare diseases and others. Therapies that are already commercialized or are forecast to be commercialized with the next five years are included.
We analyze key genetic modification therapy technologies and products to determine present and future market status and forecasted growth from 2018 through 2023. We also discuss strategic alliances, industry structures, competitive dynamics, patents and market driving forces.
This Research examines the genetic modification therapies industry by market segment, including the following segments: gene editing, gene therapy, CAR T-cell therapy, RNA therapy and lentiviral production. The geographic market for genetic modification therapy products by platform technology is analyzed. Regions include North America, Europe, Asia-Pacific and the rest of the world.
The role of key strategic alliances and acquisitions from Jan. 2016 through June 2018 is discussed.
The challenges involved with pricing for genetic modification therapies that can offer one-time cures for diseases is discussed. Emerging markets for clinical gene editing are analyzed. More than 145 companies in the genetic modification therapies industry are profiled.
The Report Includes:
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Information on the genetic variation analysis and genetic modification technologies
- Evaluation of key growth driving forces, acquisitions and strategic alliances related to the market
- Detailed description of the criteria for selecting gene modification therapy applications
- Review of patents for gene editing, gene therapy, RNA therapy and gene modification therapies
- Profiles of the key companies in the market, including 4d Molecular Therapeutics LLC, Abeona Therapeutics LLC, Acer Therapeutics Inc., Allergan Plc and American Gene Technologies International Inc
Key Topics Covered:
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing the Study
- Contribution of the Study and for Whom
- Scope and Format
- Methodology
- Information Sources
- Geographical Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Scope of Report
- Genetic Modification Therapies Covered in Report
- Genetic Modification Therapy Platform Technologies
- Forces Driving the Growth of the Market for Genetic Modification Therapies
- Global Market for Genetic Modification Therapies
- Life-Cycle Status of Products and Technologies
- Genetic Modification Therapies Industry
Chapter 4 Technology
- Introduction to Genetic Technology
- Genetic Variation and Analysis
- Genetic Modification Therapies
- Gene Therapy Technologies
- RNA Therapy Technologies
- Gene Editing Technologies
- Genetically Modified Cell Therapy Technologies
- Delivery Technologies
- Introduction
- Viral Delivery Technologies
- Nonviral Delivery Technologies
- Design and Manufacture of a Gene Therapy Medicine
Chapter 5 Genetic Modification Therapy Applications
Chapter 6 Genetic Modification Therapies Industry
- Summary
- Gene Editing Industry
- Gene Therapy Industry
- Genetically Modified Cell Therapy Industry
- RNA Therapy Industry
- Lentivirus Production Industry
Chapter 7 Acquisitions and Strategic Alliances
- Acquisitions
- Strategic Alliances
Chapter 8 Markets for Genetic Modification Therapies
- Growth Driving Forces
- Payment and Business Models for Genetic Modification Therapeutics
- Market for Genetic Modification Therapies
- Genetic Modification Therapies by Platform Technology
- Genetic Modification Therapies by Disease Category
- Genetic Modification Therapies by Delivery Technology
- Genetic Modification Therapies by Indication
- Genetic Modification Therapies by Region
Chapter 9 Patents
- Gene Editing-Related Patents
- Gene Editing Patents-Sangamo Case Study
- Gene Therapy Delivery Patents
- RNA Therapy-Related Patents
- CAR T-cell Patents
Chapter 10 Company Profiles
- 4D Molecular Therapeutics
- Abclon
- Abeona Therapeutics Llc
- Acer Therapeutics Inc.
- Adaptimmune Therapeutics
- Advantagene Inc.
- Adverum Biotechnologies
- Aevi Genomic Medicine Inc.
- Agilis Biotherapeutics
- Aldevron
- Allergan Plc
- Allogene Therapeutics Inc.
- American Gene Technologies International Inc.
- Amgen Inc.
- Anges Inc.
- Apeiron Biologics Ag
- Applied Genetic Technologies Corp.
- Arbor Biotechnologies Inc.
- Arcturus Therapeutics Inc.
- Asklepios Biopharmaceutical Inc.
- Astellas Pharma Inc.
- Audentes Therapeutics Inc.
- Avacta Group Plc
- Avrobio Inc.
- Beam Therapeutics Inc.
- Bellicum Pharmaceuticals Inc.
- Binex Co. Ltd.
- Biocurepharm Corp.
- Biogen Inc.
- Biomarin Pharmaceutical Inc.
- Bluebird Bio
- B-Mogen Biotechnologies Inc.
- Brammer Bio
- Caribou Biosciences
- Casebia Therapeutics
- Catherics Pty Ltd.
- Celgene Corp.
- Cellectis Sa
- Cell Medica Ltd.
- Cellular Biomedicine Group
- Celyad
- Cognate Bioservices
- Combigene Ab
- Crispr Therapeutics Ag
- CSL Behring Llc
- Curocell Co. Ltd.
- Editas Medicine Inc.
- Encoded Genomics Inc.
- Errant Gene Therapeutics Llc
- Esteve
- Etagen Pharma
- Eutilex Co. Ltd.
- Fate Therapeutics Inc.
- Ferring Pharmaceuticals Sa
- Fibrocell Science
- FKD Therapies Oy
- Fortress Biotech Inc.
- Freeline Therapeutics
- Ge Healthcare
- Gene Biotherapeutics Inc.
- Genenta Science Srl
- Generation Bio
- Genethon Sa
- Gensight Biologics Sa
- Gilead Sciences Inc.
- Glaxosmithkline Plc
- Global Biotherapeutics Usa Inc.
- Green Cross Cell Corp.
- Hemera Biosciences Inc.
- Hitachi Chemical Advanced Therapeutics Llc
- Homology Medicines Inc.
- Horama Sa
- Immunochina Pharmaceuticals
- Immunocore Ltd.
- Indee Labs Inc.
- Intellia Therapeutics Inc.
- Intrexon Corp.
- Jivana Biotechnology
- Johnson & Johnson
- Juventas Therapeutics Inc.
- Kolon Life Sciences Inc.
- Krystal Biotech
- Kubota Pharmaceutical Holdings Co. Ltd.
- Limelight Bio Inc.
- Logicbio Therapeutics Inc.
- Lonza Group Ltd.
- Lysogene Sa
- Marcala Biotech Inc.
- Maxcyte Inc.
- Medigene Ag
- Meira Gtx
- Merck & Co.
- Merck Kgaa
- Mesoblast Ltd.
- Millipore Sigma
- Milo Biotechnology Llc
- Molmed Spa
- Morphogenesis Inc.
- Myonexus Therapeutics Inc.
- Nantkwest Inc.
- Neximmune Inc.
- Newlink Genetics Corp.
- Nightstar Therapeutics Plc
- Novartis Pharma Ag
- Novasep Llc
- Ocunexus Therapeutics Inc.
- Orchard Therapeutics
- Oxford Biomedica Plc
- Pepromene Bio Inc.
- Periphagen Inc.
- Pfizer Inc.
- Poseida Therapeutics Inc.
- Precision Bioscience
- Regenxbio Inc.
- Renova Therapeutics
- Rocket Pharma Ltd.
- RXI Pharmaceuticals Corp.
- Sangamo Therapeutics Inc.
- Sanofi Sa
- Sarepta Therapeutics Inc.
- Selecta Biosciences Inc.
- Senti Biosciences
- Shire Plc
- Sibiono Genetech Co. Ltd.
- Sillagen Biotherapeutics
- Solid Biosciences Llc
- Spark Therapeutics Inc.
- Synpromics Ltd.
- Takara Bio
- Theragene Pharmaceuticals Inc.
- Thermo Fisher Scientific
- Tocagen
- Toolgen
- Translate Bio
- Transgene Sa
- TX Cell
- Ultragenyx Pharmaceutical Inc.
- Uniqure Nv
- Unum Therapeutics Inc.
- Vascular Biogenics Ltd.
- Viracta Therapeutics
- Viromed Co. Ltd.
- Vivet Therapeutics
- Voyager Therapeutics Inc.
- Wuxi Apptech
- Ziopharm Oncology
For more information about this report visit https://www.researchandmarkets.com/research/kx7995/global_genetic?w=12